Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its annual and special meeting of shareholders held earlier today.
新斯科舍省哈利法克斯，2024年9月17日（環球新聞專線）——專注於傳染病藥物開發和醫療對策的生物製藥公司Appili Therapeutics Inc.（多倫多證券交易所股票代碼：APLI；OTCPink：APLIF）（「公司」 或 「Appili」）今天公佈了今天早些時候舉行的年度和特別股東大會的結果。
Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.
根據收到的代理人和會議進行的投票，所有提出的決議均獲得公司股東的批准，包括下一年度的以下董事選舉：唐·西拉、布萊恩·布魯姆、特蕾莎·馬特科維茨、尤爾根·弗羅利希、阿曼德·巴爾博尼和普拉卡什·高德。
Voting results for each director are summarized below:
每位董事的投票結果彙總如下：
| Name of Nominee | Percentage of Votes For | Percentage of Votes Against |
| Don Cilla | 27,929,188 (94.54%) | 1,612,685 (5.46%) |
| Brian Bloom | 28,409,188 (96.17%) | 1,132,685 (3.83%) |
| Theresa Matkovits | 29,377,973 (99.45%) | 163,900 (0.55%) |
| Juergen Froehlich | 29,377,973 (99.45%) | 163,900 (0.55%) |
| Armand Balboni | 28,409,188 (96.17%) | 1,132,685 (3.83%) |
| Prakash Gowd | 29,377,973 (99.45%) | 163,900 (0.55%) |
| 被提名人姓名 | 的選票百分比 | 反對票百分比 |
| 唐·西拉 | 27,929,188 (94.54%) | 1,612,685 (5.46%) |
| 布萊恩·布魯姆 | 28,409,188 (96.17%) | 1,132,685 (3.83%) |
| 特蕾莎·馬特科維茨 | 29,377,973 (99.45%) | 163,900 (0.55%) |
| 尤爾根·弗羅利希 | 29,377,973 (99.45%) | 163,900 (0.55%) |
| 阿曼德·巴爾博尼 | 28,409,188 (96.17%) | 1,132,685 (3.83%) |
| Prakash Gowd | 29,377,973 (99.45%) | 163,900 (0.55%) |
All other matters considered at the Meeting were approved by shareholders, including the re-appointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration, a special resolution approving the Company's continuation (the "Continuance") from a corporation governed under the Canada Business Corporations Act to a corporation governed under the Business Corporations Act (Ontario) ("OBCA") and special resolution to authorize the board of directors of the Company, following the Continuance, to set the number of directors from time to time within the minimum and maximum number of directors set forth in the articles of the Company, in accordance with Section 125(3) of the OBCA.
會議上審議的所有其他事項均得到股東的批准，包括再次任命普華永道會計師事務所爲公司下一年度的獨立核數師，並授權公司董事確定薪酬，一項特別決議批准公司從《加拿大商業公司法》管理的公司延續（「延續」）到受《商業公司法》（安大略省）管理的公司（「OBO」）管理的公司 CA”）和授權董事會的特別決議根據OBCA第125（3）條，公司董事應遵循延期規定，不時將董事人數設定在公司章程中規定的最低和最高董事人數範圍內。
The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company's SEDAR+ profile at .
公司已就公司的SEDAR+簡介提交了會議上表決的所有決議的投票結果報告，網址爲。
About Appili Therapeutics
關於Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit .
Appili Therapeutics是一家傳染病生物製藥公司，它精心打造，以產品組合爲導向，以人爲本，以完成其解決危及生命的感染的使命。通過系統地識別需求未得到滿足的緊急感染，Appili的目標是戰略性地開發一系列新療法，以預防死亡和改善生活。該公司目前正在開發各種各樣的抗感染藥物，包括美國食品藥品管理局批准的用於治療抗微生物感染的現成甲硝唑混懸劑、消除嚴重生物武器威脅的候選疫苗以及用於治療毀容性疾病的局部抗寄生蟲藥。在久經考驗的管理團隊的領導下，Appili處於全球抗擊感染的中心。欲了解更多信息，請訪問。
Media Contact:
Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
媒體聯繫人：
珍娜·麥克尼爾，企業事務和傳播經理
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: Info@AppiliTherapeutics.com
投資者關係聯繫人：
唐·西拉，藥學博士，工商管理碩士
Appili Therapeutics
E: Info@AppiliTherapeutics.com
